Rafarma Pharmaceuticals, Inc. (RAFA) announces consolidation of
financial reports in preparation for PCAOB-Registrant Audit.
MOSCOW, Oct. 2, 2013 /PRNewswire/ -- Rafarma
Pharmaceuticals (OTC:RAFA), which previously announced plans for a
full audit and a streamlining of its corporate structure, plans to
prepare and publish consolidated financial reports in anticipation
of the audit.
As part of Rafarma's ongoing effort to streamline and
consolidate its corporate structure, revised financial reports are
being prepared which consolidate the revenue reporting of Rafarma
and its subsidiary production plant. These new reports will provide
greater transparency and will conform to GAAP principles.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art
manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces
generic antibiotics and specialty pharmaceuticals in addition to
its own line of proprietary products that are approved by the
Ministry of Health of Russian
Federation. For the last three years, the Russian Government
has been highly focused on bolstering the development of nation's
domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission
is to work with the auspices of aggressive federal initiatives to
fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit:
www.Rafarma.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend," "expect" and
similar expressions identify such forward-looking statements.
Actual results, performance or achievements could differ materially
from those contemplated, expressed or implied by the
forward-looking statements contained herein. These forward-looking
statements are based largely on the expectations of the Company and
are subject to a number of risks and uncertainties. These include,
but are not limited to: the impact of economic, competitive and
other factors affecting the Company and its operations, markets,
product, and distributor performance.
RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo
Contact:
David Anderson
801-210-7135
info@rafarma.com
SOURCE Rafarma Pharmaceuticals, Inc. (RAFA)